Home > Medicine > Other > Volume-6 > Issue-7 > RAS Mutations that Become Nonfunctional Kinase Activity

RAS Mutations that Become Nonfunctional Kinase Activity

Call for Papers

Volume-8 | Issue-6

Last date : 27-Dec-2024

Best International Journal
Open Access | Peer Reviewed | Best International Journal | Indexing & IF | 24*7 Support | Dedicated Qualified Team | Rapid Publication Process | International Editor, Reviewer Board | Attractive User Interface with Easy Navigation

Journal Type : Open Access

First Update : Within 7 Days after submittion

Submit Paper Online

For Author

Research Area


RAS Mutations that Become Nonfunctional Kinase Activity


Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi



Takuma Hayashi | Nobuo Yaegashi | Ikuo Konishi "RAS Mutations that Become Nonfunctional Kinase Activity" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-7, December 2022, pp.457-460, URL: https://www.ijtsrd.com/papers/ijtsrd52365.pdf

The rat sarcoma viral oncogene homolog (RAS) family of closely related oncogenes (KRAS, HRAS, and NRAS) are the most frequently mutated drivers of malignant transformation. RAS family highly associates the epidermal growth factor receptor (EGFR) mainly. EGF selectively binds to EGFR and triggers the receptor to form a dimer that activates RAS. RAS transmits signals from activated trans membrane receptor EGFR to effectors in the B-raf proto-oncogene (BRAF)/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling pathway in the cytoplasm. The status of RAS proteins is a negative predictive biomarker for anti-EGFR therapy in metastatic colon cancer or other malignant tumors. In here, we report that our clinical studies revealed that splicing caused by the RAS mutations, which were considered oncogenic, generates unfunctional RAS family. Especially, Kirsten Rat Sarcoma (KRAS) silent variants are of concern to be a serious problem in genomic cancer medicine.The status of rat sarcoma viral oncogene homolog (RAS) proteins is a negative predictive biomarker for anti-epidermal growth factor receptor (EGFR) therapy in metastatic colon cancer. In the phase 2 CHRONOS trial, patients with mutant gene(s) are ineligible for anti-EGFR therapy.1,2 However, our studies revealed that splicing caused by the RAS mutations, which were considered oncogenic, generates unfunctional RAS family. Especially, Kirsten Rat Sarcoma (KRAS) silent variants are of concern to be a serious problem in genomic cancer medicine.

KRAS, oncogenic variant, Cancer Genome Medicine, EGFR


IJTSRD52365
Volume-6 | Issue-7, December 2022
457-460
IJTSRD | www.ijtsrd.com | E-ISSN 2456-6470
Copyright © 2019 by author(s) and International Journal of Trend in Scientific Research and Development Journal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0)

International Journal of Trend in Scientific Research and Development - IJTSRD having online ISSN 2456-6470. IJTSRD is a leading Open Access, Peer-Reviewed International Journal which provides rapid publication of your research articles and aims to promote the theory and practice along with knowledge sharing between researchers, developers, engineers, students, and practitioners working in and around the world in many areas like Sciences, Technology, Innovation, Engineering, Agriculture, Management and many more and it is recommended by all Universities, review articles and short communications in all subjects. IJTSRD running an International Journal who are proving quality publication of peer reviewed and refereed international journals from diverse fields that emphasizes new research, development and their applications. IJTSRD provides an online access to exchange your research work, technical notes & surveying results among professionals throughout the world in e-journals. IJTSRD is a fastest growing and dynamic professional organization. The aim of this organization is to provide access not only to world class research resources, but through its professionals aim to bring in a significant transformation in the real of open access journals and online publishing.

Thomson Reuters
Google Scholer
Academia.edu

ResearchBib
Scribd.com
archive

PdfSR
issuu
Slideshare

WorldJournalAlerts
Twitter
Linkedin